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Original Article
Purpose: To compare photon thunderbird with deep match (technique 1) with 3-field technique with electron inguinal boost 
(technique 2) in acute skin toxicity, toxicity-related treatment breaks and patterns of failure in elective inguinal radiation therapy (RT) 
for curative chemoradiation in anal cancer. 
Materials and Methods: Seventeen patients treated between January 2008 and September 2010 without evidence of inguinal 
and distant metastasis were retrospectively reviewed. In 9 patients with technique 1, dose to inguinal and whole pelvis area was 
41.4 to 45 Gy and total dose was 59.4 Gy. In 8 patients with technique 2, doses to inguinal, whole pelvis, gross tumor were 36 to 
41.4 Gy, 36 to 41.4 Gy, and 45 to 54 Gy, respectively. The median follow-up period was 27.6 and 14.8 months in group technique 1 
and 2, respectively.
Results: The incidences of grade 3 radiation dermatitis were 56% (5 patients) and 50% (4 patients), dose ranges grade 3 dermatitis 
appeared were 41.4 to 50.4 Gy and 45 to 54 Gy in group technique 1 and 2, respectively (p = 0.819). The areas affected by grade 3 
dermatitis in 2 groups were as follow: perianal and perineal areas in 40% and 25%, perianal and inguinal areas in 0% and 50%, and 
perianal area only in 60% and 25%, respectively (p = 0.196). No inguinal failure has been observed.
Conclusion: Photon thunderbird with deep match technique and 3-field technique with electron inguinal boost showed similar 
incidence of radiation dermatitis. However, photon thunderbird with deep match seems to increase the possibility of severe perineal 
dermatitis.
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Introduction
For anal cancer, nonrandomized comparisons of radical 
resection with radiation-chemotherapy combination, or with 
radiation alone, have shown that radiation-based treatment 
strategies produce survival rates at least equal to those of 
surgical series, while allowing the preservation of anorectal 
function in most patients [1,2]. Recent randomized trials 
established that the combination of radiation therapy (RT), 
5-fluorouracil (5FU), and mitomycin C is the standard [2-5].
  Determining the radiation volume, treatment of the primary 
tumor and regional lymph nodes areas is recommended for all 
squamous cell cancers, except superficial well-differentiated 
tumor less than 2 cm in size [6]. Regional lymph nodes areas 
are inguinal, pararectal, and internal iliac nodes. But the 
irregularities and the curvatures of the perineum and the 
lower pelvis make homogeneous radiation distributions hard 
to achieve. 
  One of the techniques to cover the primary tumor and 
regional lymph nodes areas is photon through-and-through. 
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It consists of an anterior and posterior opposed field and 
is the simplest technique, but large volume of bowel and 
bilateral femur heads are fully irradiated [7]. To reduce the 
irradiated volume, the ‘thunderbird’ technique is conceived 
[8]. Basically, variations of thunderbird technique have the 
same field arrangements; an anterior field covering the pelvis 
and inguinal area and narrowed posterior field. An additional 
anterior field with partial transmission block is necessary 
to cover the inguinal areas, because the posterior field does 
not include them. Before the computed tomography (CT) –
based planning era, the additional photon fields were usually 
matched on the anterior skin surface (photon thunderbird 
with skin match) [7]. The problem with this technique is the 
possibility of underdosage in inguinal area. By CT-based 
planning, the additional anterior field can be matched to the 
divergent edge of the posterior pelvis field at the posterior 
edge of the femoral vessels (photon thunderbird with deep 
match) [7]. To reduce irradiated bowel volume, the technique 
moves on to the posterior pelvis technique using 3-field 
technique with electron inguinal boost [9]. 
  However, regardless of technique, grade 3 to 4 skin toxicity 
was common as 48% to 57% with non-intensity modulated 
radiotherapy (IMRT) technique and was also a common dose-
limiting structure during treatment for anal cancer [3,4]. A 
main reason for this is skin folds in the perineal, perianal, 
genital, and inguinal regions and these are common sites of 
skin toxicity. Furthermore, patients with treatment breaks or 
failure to complete RT because of treatment-associated acute 
toxicity resulted in inferior treatment outcomes [10,11].
  The purpose of the present study is to compare following 2 
CT-based techniques; photon thunderbird with deep match 
(technique 1) and 3-field technique with electron inguinal 
boost (technique 2), in acute skin toxicity, toxicity-related 
treatment breaks and patterns of failure. 
Materials and Methods
1. Patients and tumor characteristics
Between January 2008 and September 2010, 17 patients with 
squamous cell carcinoma of the anus without evidence of 
inguinal node metastasis and extra-pelvic distant metastasis 
were referred for curative chemoradiation. Their medical 
records and test results were retrospectively reviewed. The 
pretreatment evaluation included physical examination, 
routine laboratory tests, chest radiography, CT or magnetic 
resonance image (MRI) of abdomen-pelvis, sigmoidoscopy and 
tumor biopsy. In some patients, positron-emission tomography 
was performed. Fine needle aspiration was performed if 
inguinal node metastasis was clinically suspected. The tumors 
were staged according to the 2010 American Joint Committee 
on Cancer (AJCC) 7th edition [12]. The overall patient 
characteristics are given in Table 1. The median age was 55 
(range, 46 to 75 years). There were 8 men and 9 women. The 
range of tumor size was 0.4 to 4 cm (mean, 2.4 cm). Three 
patients had clinically T4 stage due to vaginal and prostate 
involvement in 2 and 1, respectively. Synchronous lymph node 
metastases were observed in 7 patients (42%). Mesorectal 
node metastasis was shown in 3 patients, mesorectal and 
ipsilateral pelvic side wall node metastasis in 2, ipsilateral 
internal iliac node metastasis in 1, and mesorectal, ipsilateral 
pelvic side wall and external iliac node metastasis in 1 patient. 
  Comparisons of the patients and tumor characteristics 
between 2 groups are given in Table 2. Group technique 1 had 
more poorly differentiated tumors, more N+ stages, so more 
stage III patients, without statistical significance. 
2. Treatment methods
Tables 1 and 2 contain brief treatment methods. Transanal 
mass excision was performed in 6 patients with stage I or 
II. CT-based treatment planning was performed for all 17 
patients. All patients were treated in supine position with 
2-hour bladder filling. The upper limit of the pelvic irradiation 
fields was situated between L5 and S1, and the lower limit 
was 2 to 2.5 cm below the anus. Fraction size was 1.8 Gy and 
treatment was performed 5 times per week. 
  1) RT plan and dose in group technique 1 (thun­
derbird technique): 10 MV photon beams were used for 
antero-posterior and postero-anterior beams and anterior 
inguinal photon boost fields (Fig. 1). Inguinal lymph node 
areas were delineated in each patient for inguinal boost fields. 
Patients with N0, single N1 or N2 disease received 41.4 Gy and 
patients with multiple N2 disease received 45 Gy to whole 
pelvis and inguinal area. 
  Primary tumor areas were irradiated to 59.4 Gy. Gross 
metastatic lymph nodes were irradiated to 50.4 to 59.4 Gy, 
depending on the size and location of the gross lesion. For 
reduced fields, 6 MV posterior photon and 10 MV lateral 
opposing photon beams were used to cover primary tumor and 
metastatic lymph nodes, and for second cone down, 10 MV 
5 photon beams were used to cover primary tumor area. In 4 
patients with lymph node metastasis, field shrinkage was done 
twice. Exceptionally, in a patient with external iliac lymph node 
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metastasis, anterior 2 ports of 6 MV photon beams were used 
to cover the gross metastatic node and 6 MV posterior photon 
and 10 MV lateral opposing photon beams were used to cover 
primary tumor.
   2) RT plan and dose in group technique 2 (electron 
inguinal node boost technique): 6 MV posterior photon 
and 10 MV lateral opposing photon beams were used for whole 
pelvis field. Each inguinal boost field was planned in octagonal 
shape [13], and electrons of 9 to 12 MeV were used depending 
on the depth of inguinal lymph node area (Fig. 2). In 5 of 8 
patients, inguinal RT was given to 36 Gy and whole pelvis was 
to 45 Gy. In 2 patient with T1N0 disease showed less than 1.5 
cm tumor size, 36 Gy of inguinal RT in both and 36 Gy and 
41.4 Gy of whole pelvis irradiation in each were performed. In 
a patient with T4N0, inguinal and whole pelvis RT was to 41.4 
Gy. For patients with stage I and II of tumor size less than 3 
cm, 45 Gy to 50.4 Gy of total dose were given. Otherwise, 54 
Gy of total dose was delivered to gross tumor area. 10 MV 5 
photon beams were used to cover primary tumor areas for 
cone down plan. 
  3) Chemotherapy: Concomitant chemotherapy was 
Table 1. Patients characteristics and treatments
Characteristics No. of patients (%)
Age (yr), median (range) 55 (46-75)
Sex
Male 8 (47)
Female 9 (53)
Pathology
WD 1 (6)
MD 3 (18)
PD 3 (18)
Unspecified 10 (58)
Stage 
I 5 (28)
II 4 (24)
IIIA 3 (18)
IIIB 4 (24)
IV 1 (6)
T classification  
T1 7 (41)
T2 7 (41)
T3 0 (0)
T4 3 (18)
N classification  
N0 10 (58)
N1 3 (18)
N2 4 (24)
Transanal excision  
Yes 6 (36)
No 11 (64)
Radiation technique  
Technique 1 9 (53)
Technique 2 8 (47)
Chemotherapy regimen 
5FU/mitomycin 12 (70)
5FU/cisplatin 4 (24)
5FU 1 (6)
WD, well differentiation; MD, moderate differentiation; PD, poor 
differentiation; 5FU, 5-fluorouracil.
Table 2. Patients characteristics and treatments in each group
No. of patients (%)
p-value
Technique 1 Technique 2
Age (yr)   0.245
Median (range) 59 (46-71) 55 (49-75)
Sex   0.086
Male 6 (67) 2 (25) 
Female 3 (33) 6 (75) 
Pathology   0.073
WD 1 (11) 0 (0) 
MD 0 (0) 3 (37.5) 
PD 3 (33) 0 (0) 
Unspecified 5 (56) 5 (62.5) 
Stage   0.35
I 1 (11) 4 (50) 
II 2 (22) 2 (25) 
IIIA 2 (22) 1 (12.5) 
IIIB 3 (33) 1 (12.5) 
IV 1 (11) 0 (0) 
T classification   0.425
T1 3 (33) 4 (50) 
T2 5 (56) 2 (25) 
T3 0 (0) 0 (0) 
T4 1 (11) 2 (25) 
N classification   0.052
N0 3 (33) 7 (87.5) 
N1 2 (22) 1 (12.5) 
N2 4 (45) 0 (0) 
Transanal excision   0.858
Yes 3 (33) 3 (37.5) 
No 6 (67) 5 (62.5) 
Chemotherapy regimen   0.378
5FU/mitomycin 6 (67) 6 (75) 
5FU/cisplatin 3 (33) 1 (12.5) 
5FU 0 (0) 1 (12.5) 
WD, well differentiation; MD, moderate differentiation; PD, poor 
differentiation; 5FU, 5-fluorouracil.
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delivered to all 17 patients. 5FU and mitomycin regimen was 
given to 70% (12 patients), 5FU and cisplatin was to 24% (4 
patients) and 5FU monotherapy was to 1 patient. Twenty-
percent reduced dose was delivered to 3 patients over age 70. 
Two cycles of adjuvant chemotherapy was given to 1 patient 
with external iliac lymph node metastasis. There was no 
significant difference in chemotherapy between 2 groups (Table 
2). 
3. Follow-up
During the treatment, patients were examined weekly to 
assess the area and grade of radiation dermatitis and other 
treatment-associated toxicities. Radiation dermatitis and other 
treatment-associated toxicities were assessed according to the 
Radiation Treatment Oncology Group (RTOG) common toxicity 
criteria [14] (Table 3).
  The assessments of the tumor response were made 1 to 3 
Fig. 1. Beam’s eye views (A) and isodose curve (B) of photon thunderbird with deep match (technique 1). 
Fig. 2. Beam’s eye views (A) and isodose curve (B) of 3-field technique with electron inguinal boost (technique 2).
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months after the completion of RT. CT or MRI of abdomen-
pelvis and colonoscopy were performed and biopsy was done 
if suspicious area still existed at post-RT 3 months. 
  The median follow-up period from the beginning of treat-
ment for entire patients was 21.8 months (range, 11.1 to 43.6 
months). The median follow-up period according to the RT 
technique was 27.6 months (range, 17.5 to 43.6 months) in 
the group technique 1 and 14.8 months (range, 11.1 to 27.2 
months) in the group technique 2. 
4. Statistical analysis
The proportions and mean values were compared by the chi-
square test and 2-independent samples test. Survival rates 
were estimated according to the Kaplan-Meier method. The 
survival rates were calculated from the beginning of treatment. 
Results
1. Acute toxicities and treatment breaks
All patients completed planned chemoradiation. In group 
technique 1, the incidence of grade 3 radiation dermatitis 
was 56% (5 patients). The range of radiation dose that grade 
3 radiation dermatitis observed was 41.4 to 50.4 Gy. The 
affected areas were perianal and perineal area including vulvar 
or scrotal regions in 2 of 5 patients (40%) and perianal area 
only in 3 of 5 patients (60%) (Table 4). Thirty-three percent 
(3 patients) of group technique 1 had treatment breaks. Two 
patients with grade 3 radiation dermatitis needed breaks 
at the dose of 50.4 Gy for 6 and 10 days, respectively. The 
other patient needed 4 days treatment break because of 
thrombocytopenia less than 40,000/μL at the dose of 48.6 Gy. 
  In group technique 2, the incidence of grade 3 radiation 
dermatitis was 50% (4 patients). The range of radiation dose 
that grade 3 radiation dermatitis observed was 45 to 54 Gy. 
The affected areas were perianal and inguinal area in 2 of 4 
patients (50%), perianal and perineal area in 1 of 4 (25%), 
and perianal area only in 1 of 4 patients (25%). None of the 
patients in group technique 2 needed treatment break (Table 4). 
  Comparing the 2 groups, there was no difference in the 
incidence of grade 3 radiation dermatitis (p = 0.819) and dose 
of grade 3 radiation dermatitis (p = 0.457). Comparison of the 
affected areas by grade 3 dermatitis was done for affected 5 
patients with technique 1 and 4 patients with technique 2, and 
the difference was not statistically significant (p = 0.196) (Table 
4). 
2. Late complication and sphincter conservation
One patient experienced hematochezia at post-RT 2 years and 
2 months. Colonoscopy was performed and grade 2 radiation 
proctitis was confirmed. Hemostasis to dilated blood vessel 
was done. The patient was in group technique 1 with 5FU/
cisplatin chemotherapy. The dose to whole pelvis was 45 Gy 
and total dose was 59.4 Gy. None of the patients underwent 
colostomy. There was no leg edema and fibrosis of inguinal 
area.
3. Tumor responses
After initial response evaluation, 7 of 9 patients in group 
technique 1 and 6 of 8 patients in group technique 2 were 
Table 3. Radiation Treatment Oncology Group (RTOG) common 
toxicity criteria - acute skin toxicity [14]
Grade Sign
0
1
2
3
4
5
No symptoms
Follicular, faint or dull erythema/epilation/dry
  desquamation/decreased sweating
Tender or bright erythema, patchy moist
  desquamation/moderate edema
Confluent, moist desquamation other than skin 
  folds, pitting edema
Ulceration, hemorrhage, necrosis
Death
Table 4. Treatment-associated toxicities and treatment breaks
Technique 1
(n = 9)
Technique 2
(n = 8)
p-value
Radiation dermatitis
  ≥ grade 3
Dose range of radiation 
  dermatitis ≥ grade 3 
  appeared (Gy)
Treatment breaks due to 
  radiation dermatitis
Areas of radiation
  dermatitis ≥ grade 3b) 
    Perianal and perineal
    Perianal and inguinal
    Perianal only
 5 (56)
41.4-50.4
 2 (22)
  2 (40)
0 (0)
  3 (60)
 4 (50)
45-54
0 (0)
  1 (25)
  2 (50)
  1 (25)
0.819
 
 0.457a)
0.156
0.196
Values are presented as number (%). 
a)A p-value from Mann-Whitney U-test. b)The percentage of each 
area in each group and data analysis were done in patients with 
grade 3 radiation dermatitis; 5 patients in group technique 1 
and 4 patients in group technique 2.
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considered in clinical complete remission. Rest of them 
underwent colonoscopic biopsies of suspicious lesions and all 
resulted as tumor free. Therefore, all patients gained clinical 
complete remission. 
4. Patterns of failure
Two patients experienced recurrences. Local recurrence was 
observed in one patient 12.5 months after the treatment. The 
patient was initially T2N2M0 and treated by technique 1 with 4 
days treatment break because of thrombocytopenia. After the 
diagnosis of recurrence, the patient was referred to another 
hospital for her preference. 
  The other patient experienced distant failure 14.7 months 
after the chemoradiation. The patient initially had stage T2N2 
with external iliac lymph node metastasis. The locations of 
distant metastasis were lung and supraclavicular lymph nodes. 
He received palliative chemotherapy but died of the disease 
after 6 months after the diagnosis of recurrence. 
  No recurrence was observed in inguinal lymph node area.
5. Survival rates
At analysis, only 1 patient died of the disease and the patient 
was in group technique 1. Three-year disease-free survival rate 
of group technique 1 and 2 was 75% and 100% (p = 0.251), 
and 3-year overall survival rate was 88% and 100% (p = 0.617), 
respectively. 
Discussion and Conclusion
This study includes a series of 17 patients with squamous 
cell carcinoma of the anus without inguinal and extrapelvic 
metastasis, underwent curative chemoradiation including 
elective inguinal RT. Information from this study may be 
helpful in making decisions about techniques for inguinal RT 
and predicting treatment-associated toxicities. 
  The optimal dose of elective inguinal RT to control the 
disease is unclear. A couple of studies reported that after 
30 Gy of elective inguinal RT in conventional fractionation, 
patients with clinically negative inguinal nodes at presentation 
are at minimal risk for inguinal failure [13]. The study of 233 
clinical N0 patients received 40 Gy of elective inguinal RT 
resulted in 94.8% of inguinal control rate [15]. In our study, 
dose of inguinal RT varied from 36 to 45 Gy depending on the 
technique and stage. No inguinal failure has been observed, 
and the dose range seems to be acceptable.
  In the beginning time of curative radiation for anal cancer, 
the incidence of perineal skin reaction was 70%, despite the 
low radiation dose [16]. Adding chemotherapy improved 
disease control rate but also increased the incidence of severe 
toxicities. In RTOG 87-04/EORTC 1289 study, overall rate of 
grade 3 or more toxicity was 62 to 78% depending on the 
chemotherapy regimen, and the rate of grade 3 or more 
radiation dermatitis was 55% from whole pelvis dose of 30.6 to 
36 Gy. Above all, proportion of patients completed the protocol 
was only 79%, and the major radiation-induced dose-limiting 
toxicity was radiation dermatitis [5]. In addition, multiple 
studies suggested that patients with longer gap duration or 
overall treatment time had worse treatment outcome [17-
19]. From that, effort to reduce severe radiation dermatitis has 
been made by introducing new technique and assessing its 
usefulness compare to the 2-dimensional treatment planning. 
RTOG 98-11 study accepted CT-based 3- or 4-field technique 
for whole pelvis RT and despite the dose escalation of 36 Gy to 
the whole pelvis and 45 Gy to the true pelvis (below the level 
of sacroiliac joint), the incidence of grade 3 or more radiation 
dermatitis was reduced by 44% in total [20]. In our study, 
whole pelvis dose was 41.4 to 45 Gy by technique 1 and 36 to 
45 Gy by technique 2, while the incidence of grade 3 or more 
radiation dermatitis was 56% and 50%, respectively. The slight 
higher incidence in our study might be due to the higher pelvic 
dose. 
  This study has limitations coming from its retrospective 
nature and small patient number. We cannot derive statistically 
significant results, but can find certain trends, which reflects 
that patients in each group received RT in homogeneous 
technique. 
  Comparing 2 different techniques, group technique 1 showed 
trend of earlier development of grade 3 radiation dermatitis 
despite the same dose range to the whole pelvis. Also the 
affected areas were tend to be wider including the perineal 
area while patients with technique 2 mainly showed separated 
affected areas as perianal and ingunal. But it is uncertain 
whether these factors are the whole reasons of treatment 
breaks in group technique 1 because of the higher total dose 
compared with the group technique 2. 
  In conclusion, photon thunderbird with deep match 
technique and 3-field technique with electron inguinal boost 
showed similar incidence of radiation dermatitis. However, 
photon thunderbird with deep match seems to increase the 
possibility of severe perineal dermatitis.
Jihye Cha, et al
242 www.e-roj.org http://dx.doi.org/10.3857/roj.2011.29.4.236
Conflict of Interest
No potential conflict of interest relevant to this article was 
reported.
References
1. Pocard M, Tiret E, Nugent K, Dehni N, Parc R. Results of 
salvage abdominoperineal resection for anal cancer after 
radiotherapy. Dis Colon Rectum 1998;41:1488-93.
2. Valentini V, Mantello G, Luzi S, Macchia G, Manfrida S, 
Smaniotto D. Cancer of the anal canal and local control. Rays 
1998;23:586-94.
3. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, 
mitomycin, and radiotherapy vs fluorouracil, cisplatin, and 
radiotherapy for carcinoma of the anal canal: a randomized 
controlled trial. JAMA 2008;299:1914-21.
4. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant 
radiotherapy and chemotherapy is superior to radiotherapy 
alone in the treatment of locally advanced anal cancer: results 
of a phase III randomized trial of the European Organization 
for Research and Treatment of Cancer Radiotherapy 
and Gastrointestinal Cooperative Groups. J Clin Oncol 
1997;15:2040-9.
5. Flam M, John M, Pajak TF, et al. Role of mitomycin in 
combination with fluorouracil and radiotherapy, and of 
salvage chemoradiation in the definitive nonsurgical 
treatment of epidermoid carcinoma of the anal canal: results 
of a phase III randomized intergroup study. J Clin Oncol 
1996;14:2527-39. 
6. Chao KSC, Perez CA, Brady LW. Radiation oncology: 
management decisions. 3rd ed. Philadelphia: Wolters Kluwer 
Health/Lippincott Williams & Wilkins; 2011. 
7. Gilroy JS, Amdur RJ, Louis DA, Li JG, Mendenhall WM. 
Irradiating the groin nodes without breaking a leg: a 
comparison of techniques for groin node irradiation. Med 
Dosim 2004;29:258-64.
8. Ma L, Chang W, Lau-Chin M, Tate EM, Boyer AL. Using static 
MLC fields to replace partial transmission cerrobend blocks 
in treatment planning of rectal carcinoma cases. Med Dosim 
1998;23:264-6.
9. Koh WJ, Chiu M, Stelzer KJ, et al. Femoral vessel depth and the 
implications for groin node radiation. Int J Radiat Oncol Biol 
Phys 1993;27:969-74.
10. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell 
carcinoma of the anal canal: predictors of treatment outcome. 
Dis Colon Rectum 2008;51:147-53. 
11. Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, 
DeLaney TF. Time-dose considerations in the treatment of anal 
cancer. Int J Radiat Oncol Biol Phys 1997;39:651-7.
12. Edge SB; American Joint Committee on Cancer. AJCC cancer 
staging manual. 7th ed. New York: Springer; 2010.
13. Cox JD, Ang KK. Radiation oncology: rationale, technique, 
results. 9th ed. Philadelphia, PA: Mosby; 2010. 
14. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation 
Therapy Oncology Group (RTOG) and the European 
Organization for Research and Treatment of Cancer (EORTC). 
Int J Radiat Oncol Biol Phys 1995;31:1341-6.
15. Touboul E, Schlienger M, Buffat L, et al. Epidermoid carcinoma 
of the anal canal: results of curative-intent radiation therapy 
in a series of 270 patients. Cancer 1994;73:1569-79.
16. Cho CC, Taylor CW 3rd, Padmanabhan A, et al. Squamous-
cell carcinoma of the anal canal: management with combined 
chemo-radiation therapy. Dis Colon Rectum 1991;34:675-8.
17. Deniaud-Alexandre E, Touboul E, Tiret E, et al. Results of 
definitive irradiation in a series of 305 epidermoid carcinomas 
of the anal canal. Int J Radiat Oncol Biol Phys 2003;56:1259-
73.
18. Graf R, Wust P, Hildebrandt B, et al. Impact of overall 
treatment time on local control of anal cancer treated with 
radiochemotherapy. Oncology 2003;65:14-22.
19. Weber DC, Kurtz JM, Allal AS. The impact of gap duration on 
local control in anal canal carcinoma treated by split-course 
radiotherapy and concomitant chemotherapy. Int J Radiat 
Oncol Biol Phys 2001;50:675-80.
20. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors 
derived from a prospective database dictate clinical biology 
of anal cancer: the intergroup trial (RTOG 98-11). Cancer 
2010;116:4007-13.
